All In Biotech

Drug Trial Radar · NCT05234437

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

A Phase IIb, Multicentre, Open Label Study to Evaluate the Effectiveness, Safety and Tolerability of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Last checked: Nov 20, 2026Latest source record: Apr 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Mar 9, 2022

Primary completion

Jul 18, 2022

Study completion Jul 18, 2022

Sponsor

Lead sponsor
QBiotics Group LimitedIndustry
Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma

Conditions

  • Melanoma

Interventions

  • tigilanol tiglateDrug

    Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2. Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumour ResponsesTime frame: 36 months
  2. Tumour AblationTime frame: 36 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • Cairns and Hinterland Hospital and Health Service

    Cairns, Queensland, Australia

  • Metro South Hospital and Health Service via Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.